Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

Post by snuff133on Apr 07, 2022 8:31am
257 Views
Post# 34583512

News !!!

News !!! Dear Friend;
 
Attached is today’s news release announcing AngioPro and AngioConsult as distributors in Europe for the VMS+ products (2D, 3D and MRI analysis packages)
 
Here is some background:
 
1. We have been interviewing distributors for many months as we need a distributor who knows how to sell innovative new cardiovascular medical devices and Angiopro with their consulting group AngioConsult bring both market reach and awareness.
2. Our strategy here is to have independent distributors selling along side General Electric Healthcare Corp (GEHC) to address all of the market - GEHC only has partial market share and this their market share in Europe is lower than in North America.
3. We view this a synergistic as most echocardiography services have ultrasound machines from 2-3 vendors such as GEHC, Philips, Siemens, etc and so these cardiologists will have multiple sales reps making them aware of the VMS+ advantages.
4. I am happy to report that CardioLogic, our distributor iin the UK, is reporting a positive engagement with the NICE group within the NHS and is also now demonstrating the VMS+ to customers.
5. We are also engaged in discussions with a national distributor for the USA, which would greatly expand our sales efforts there.
6. We continue to engage leading cardiologists and have 15 clinical projects that have been initiated by these KOLs and which are funded by the host institution.  This is an amazing sign of the value our products bring to everyday cardiology.
7. I know it has been a long time to begin to see significant adoption of the VMS+, but it is happening.
 
Thank you for your continued support and interest as we go forward to improve cardiac diagnostics for everyone worldwide and especially for children.
 
Regards,
 
Dr. George Adams ICD.D
Executive-Chairman
Ventripoint Diagnostics Ltd.
TSXV-VPT

<< Previous
Bullboard Posts
Next >>